Skip to main content
OpenTrials

Clinical trial condition

Hemostatic Disorders

Explore clinical trials studying Hemostatic Disorders. Study availability and eligibility vary by location and protocol.

3,072 public trials 579 recruiting studies
Refine in advanced search Browse all conditions

Hemostatic Disorders trial results

Active, Not Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details
Active, Not Recruiting

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

NCT04166565

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Extramedullary Plasmacytoma, +13 more
Locations
  • University of Athens Athens, Greece
  • Anticancer Hospital of Thessaloniki Thessaloniki, Greece
  • University of Bologna Bologna, Italy
  • Univerity of Turin Torino, Italy
View Trial Details
Active, Not Recruiting

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Banner Gateway Medical Center Gilbert, Arizona, United States
  • Banner Gateway Medical Pavilion Gilbert, Arizona, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Ronald Reagan UCLA Medical Center Los Angeles, California, United States
View all 209 locations
View Trial Details
Active, Not Recruiting

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

NCT05675449

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Beverly Hills Cancer Center Beverly Hills, California, United States
  • Clinical Research Advisors (Encino Satellite Location) Encino, California, United States
  • Clinical Research Advisors (Korea Town Satellite Location) Los Angeles, California, United States
View all 36 locations
View Trial Details
Active, Not Recruiting

Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients

NCT06062537

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • CHU Amiens Picardie Amiens, France
  • CH d'ANNECY Annecy, France
  • Centre hospitalier d'Argenteuil Argenteuil, France
  • Hopital de la cote Basque Bayonne, France
View all 31 locations
View Trial Details
Active, Not Recruiting

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05572515

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Alta Bates Comprehensive Cancer Center Berkeley, California, United States
  • MemorialCare Long Beach Medical Center Long Beach, California, United States
View all 211 locations
View Trial Details

Related conditions